Literature DB >> 11181557

Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.

S Polzer1, M T Dittmar, H Schmitz, B Meyer, H Müller, H G Kräusslich, M Schreiber.   

Abstract

We describe mutants of human immunodeficiency virus type-1 (HIV-1) strain NL4-3, which are lacking the thirteenth, fifteenth, or seventeenth sites for N-linked glycosylation (g13, g15, g17) of the envelope protein gp120. All three sites are located within the hypervariable V3 loop region of gp120. Those mutants lacking carbohydrates g15 or combinations of g15/g17 showed markedly higher infectivity for GHOST cells (human osteosarcoma cells) expressing CXCR4 (GHOST-X4), compared to the fully glycosylated NL4-3 wild type virus. In addition, these mutants could also infect cells which exhibits low background expression of CXCR4, corresponding to <10% of that observed for GHOST-X4 cells. In addition to the enhanced infectivity observed, mutants lacking g15 and g17 showed increased resistance to inhibition by SDF-1, the natural ligand of CXCR4. Thus, loss of the oligosaccharides g15 and g17 in the V3 region of gp120 markedly influences CXCR4-specific infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181557     DOI: 10.1093/glycob/11.1.11

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  17 in total

1.  Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.

Authors:  M Gordon; T De Oliveira; K Bishop; H M Coovadia; L Madurai; S Engelbrecht; E Janse van Rensburg; A Mosam; A Smith; S Cassol
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.

Authors:  Jenny M Cutalo; Leesa J Deterding; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2004-11       Impact factor: 3.109

3.  Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Authors:  Rajnish Kumar; Michael Tuen; Jianping Liu; Arthur Nàdas; Ruimin Pan; Xiangpeng Kong; Catarina E Hioe
Journal:  Vaccine       Date:  2013-09-16       Impact factor: 3.641

4.  A recombinant virus assay using full-length envelope sequences to detect changes in HIV-1 co-receptor usage.

Authors:  M T Dittmar; S Eichler; S Reinberger; L Henning; H G Kräusslich
Journal:  Virus Genes       Date:  2001-12       Impact factor: 2.332

5.  Mutation of a Single Envelope N-Linked Glycosylation Site Enhances the Pathogenicity of Bovine Leukemia Virus.

Authors:  Alix de Brogniez; Amel Baya Bouzar; Jean-Rock Jacques; Jean-Philippe Cosse; Nicolas Gillet; Isabelle Callebaut; Michal Reichert; Luc Willems
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

6.  Analysis and function of prototype foamy virus envelope N glycosylation.

Authors:  Daniel Lüftenegger; Marcus Picard-Maureau; Nicole Stanke; Axel Rethwilm; Dirk Lindemann
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.

Authors:  Tobias Wolk; Michael Schreiber
Journal:  Med Microbiol Immunol       Date:  2006-03-18       Impact factor: 3.402

8.  Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.

Authors:  Shi-Hua Xiang
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

9.  Ramified feline microglia selects for distinct variants of feline immunodeficiency virus during early central nervous system infection.

Authors:  Andreas Hein; Holger Schuh; Simone Thiel; Jean-Pierre Martin; Rüdiger Dörries
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

10.  Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence.

Authors:  Ravi Kumar; Gajendra P S Raghava
Journal:  PLoS One       Date:  2013-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.